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ABSTRACT 
Streptococcus pyogenes and Staphylococcus aureus are Gram-positive bacteria that share 
many features, including clinical presentations and pathogenic mechanisms, and yet, they 
still have unique properties. They both cause diseases ranging from uncomplicated 
infections to severe invasive diseases, such as sepsis and toxic shock syndrome, as well as 
severe tissue infections including necrotizing fasciitis and necrotizing pneumonia. While 
S. pyogenes is susceptible to penicillin, the public health concern regarding 
staphylococcal infections is enhanced by the increasing prevalence of methicillin-resistant 
S. aureus. Neutrophils have a central role as the first line of defense against bacteria, by 
killing invaders through phagocytosis, neutrophil extracellular trap formation or 
degranulation. Neutrophil granules contain a variety of proteins that contribute to 
antimicrobial defense. However, degranulation and release of these proteolytic and 
inflammatory factors in the tissue milieu can also be harmful to the host. This thesis 
project explored interactions between neutrophils and both Gram-positive species, with a 
particular focus on neutrophils as potential contributors to the pathogenesis of these 
infections. 
In paper I we investigated the neutrophil response towards streptococcal factors secreted 
by different clinical isolates. We identified phosphoglycerate kinase (PGK), a 
moonlighting protein with glycolytic function, as a novel, potent neutrophil activator with 
the ability to trigger degranulation. PGK was found to be susceptible to proteolytic 
degradation by SpeB and consequently SpeB-negative strains elicited stronger neutrophil 
responses. This finding is of interest, as hypervirulent SpeB-negative strains are 
associated with invasive streptococcal infections. 
In paper II we studied the effect of sub-inhibitory concentrations of LL-37 on S. 
pyogenes, as these concentrations have been reported to alter virulence gene expression. 
We showed that LL-37 induced the release of extracellular vesicle-like structures, which 
contained several virulence factors with immunostimulatory properties. This is the first 
report of vesicle-like structures release by S. pyogenes in response to LL-37. The presence 
of virulence factors in these vesicles and the pro-inflammatory effect towards neutrophils 
implicates a potential role for LL-37 in S. pyogenes pathogenesis. 
In paper III we focused on bi-component leukocidins from S. aureus and their effect on 
neutrophil degranulation. PVL and LukED had a dose-dependent effect on cytotoxicity. 
However, neutrophil degranulation showed a different pattern. While PVL triggered even 
at sub-lytic concentrations neutrophil granule exocytosis, this event was only seen when 
lytic concentrations of LukED were used. Determination of the whole neutrophil 
secretomes triggered by lytic and sub-lytic concentrations of PVL and LukED revealed 
significantly different response profiles. This study demonstrates that neutrophil 
activation and degranulation in response to S. aureus pore-forming toxins depends on 
both the type and concentration of toxin. PVL was found to be a potent activator even at 
sublytic concentrations.  
In summary, we identified the streptococcal factor PGK, as well as the pore-forming 
toxins from S. aureus as potent triggers of neutrophil activation and degranulation. In 
addition, we show that the antimicrobial peptide LL-37 induces the release of pro-
inflammatory extracellular vesicle-like structures from the surface of S. pyogenes. 
Together, these studies demonstrate specific neutrophil responses triggered by Gram-
positive bacterial virulence factors, which is in line with a likely contribution to disease 
pathogenesis. 
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BACKGROUND 
1.1 THE IMMUNE SYSTEM – AN OVERVIEW 
Our body is protected by our immune system, which consists of different cells, tissues and 
organs and can be divided into innate and adaptive immunity (Figure 1) [1]. Innate 
immunity is characterized by the immediate and unspecific response to a microbial 
assault. In contrast, the adaptive immune response takes more time to become activated, 
but is very specific. Additionally, the adaptive arm of the immune response is endowed 
with an immunological memory of specific invaders.  
 
 
Figure 1. Principal mechanisms of innate and adaptive immunity. Innate immunity provides initial 
defense against invaders, such as epithelial barriers, different cells, e.g. phagocytes, and the complement 
system. The adaptive immunity develops later and consists of B and T lymphocytes. The recognition of 
microbes is mediated through specific receptors, following proliferation of the lymphocytes. Antibodies 
produced by plasma cell bind to microbes and label them for destruction by phagocytes. Effector T cells can 
eliminate infected cells by inducing apoptosis. Adapted and modified from [2]. 
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Adaptive Immunity 
T- and B-lymphocytes are the major players in adaptive immune response (Figure 1) [1]. 
Both are produced in the bone marrow and have a diverse repertoire of receptors, either T 
cell receptors (TCRs) or B cell receptors (BCRs), which can recognize almost any 
intruder. While T cells recognize specific peptides derived from protein antigens, which 
are presented by infected cells via MHC class I or class II molecules, B-cells themselves 
are able to recognize any organic antigen without presentation.  
T cells mature in the thymus where they differentiate into two different subsets. 
Depending on the type of glycoprotein (also known as co-receptors), they express on their 
surface, they are called either CD4+ or CD8+ T cells. CD4+ T cells, also referred to as T 
helper (TH) cells, assist other immune cells during infection. They recognize peptides, 
degraded from exogenous antigens that are presented by professional phagocytes (APCs) 
like Dendritic Cells (DCs), macrophages and B-cells via MHC class II. CD8+, or 
cytotoxic T lymphocytes (CTLs), recognize peptides degraded from exogenous and 
endogenous antigens presented via MHC class I on any nucleated cell [3]. If a cell is 
infected, CTLs can kill it by inducing apoptosis. 
B cells mature in the bone marrow and can produce large amounts of antibodies. These 
antibodies can help to neutralize virulence factors and to eliminate invaders by binding to 
antigens. This either prevents entry into and the subsequent infection of cells and/or will 
mark the pathogen for destruction by phagocytes (opsonization). 
 
Innate Immunity 
It takes some time for the adaptive immune response to produce antibodies and/or 
increase the numbers of involved cells (by proliferation or clonal expansion). The innate 
immune system however reacts immediately upon the detection of foreign structures and 
is the first line of our defense against foreign bodies. It consists of a physical barrier – the 
skin and mucosa – that protects us from invading pathogens [4]. Once this barrier is 
breached there are professional phagocytes, such as macrophages, DCs and neutrophils, 
natural killer (NK) cells, antimicrobial peptides (AMPs), cytokines and components of the 
complement system present to face and neutralize these invaders [4]. When it comes to 
bacterial infections, neutrophils play a crucial role as they are amongst the first immune 
cells recruited to the site of infection (Figure 1). 
   3 
1.2 NEUTROPHILS AND THEIR ROLE IN THE HOST DEFENSE 
AGAINST PATHOGENS 
1.2.1 Neutrophils 
Neutrophils are part of the innate immune system and belong to the group of granular 
leukocytes (granulocytes), as determined by the presence of different granules in their 
cytoplasm. In contrast, lymphocytes and monocytes are referred to as non-granular 
leukocytes. The shape of the nucleus, which is “folded” into three segments, has given the 
granulocytes the name polymorphonuclear (PMN) cells.  
Neutrophils are derived from the bone marrow and make up around 70% of our 
circulating leukocytes. Every day, up to 0.5-1x1011 neutrophils are produced in the bone 
marrow [5] and this is controlled by granulocyte colony stimulatory factor (G-CSF) [6]. 
During inflammation or in response to the increased apoptosis of neutrophils, the rate of 
neutrophil production can also be augmented by IL-17 and other cytokines released by TH 
cells [7]. Neutrophils are generally thought to be short-lived cells, with a half-life of only 
7h in circulation [8]; however, recently, it has been shown by Pillay et al. that circulating 
neutrophils can have a lifespan of around 5.4 days [9]. An explanation for this 
discrepancy in neutrophil lifespan could be a result of methodological problems in the 
labeling of neutrophils, as suggested by Tak et al. [10]. On the other hand, more and more 
data is emerging regarding additional neutrophil functions aside from their roles in the 
innate immune response and pathogen killing, e.g. modulation of B and T cell activation 
[11], which supports the argument that neutrophils have a longer lifespan.  
 
1.2.2 Chemotaxis, priming and activation 
Neutrophils circulate in the blood and are “on call”, waiting for chemokine signals from 
infected tissue. If an invader is detected, neutrophils leave the blood stream and migrate 
into the targeted tissue, which involves different steps: tethering, rolling, adhesion, 
crawling and transmigration (Figure 2) [11].  
Sentinel cells in tissue, such as macrophages, mast cells or DCs, release cytokines in 
response to pathogens or other danger signals. This induces changes in the endothelial 
cells present in the nearby blood vessels. Besides this indirect activation, endothelial cells 
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can also be activated by direct recognition of pathogens through pattern recognition 
receptors (PRRs). 
 
 
Figure 2. Neutrophil recruitment to sites of inflammation. 1) Circulating neutrophils are captured by 
selectins (P and E), which are expressed on the surface of stimulated endothelial cells, followed by selectin-
mediated rolling (2). Integrin-integrin interactions result in firm adhesion (3) and final transmigration (4) 
through the endothelium to the site of infection. Adapted and modified from [12]. 
 
As a consequence of either indirect or direct recognition of pathogens, endothelial cells 
up-regulate different selectins (P- and E-selectin). Neutrophils express the complementary 
ligand P-selectin glycoprotein 1 (PSGL-1) on their surface, which interacts with the 
epithelial selectins. Through this interaction and the constant breaking and formation of 
new bonds between the selectins and neutrophils, the neutrophil speed slows down 
(tethering). Once the neutrophil speed is reduced (rolling), interactions between the 
integrins ICAM-1 and -2 (intercellular adhesion molecule-1; 2) present on endothelial 
cells with LFA-1 (lymphocyte function associated antigen-1) and Mac-1 (macrophage-1 
antigen) on neutrophils, lead to closer contact (adhesion) (Figure 2).  
Pro-inflammatory cytokines like TNFα (tumor necrosis factor alpha) and IL-1β 
(interleukin-1 beta) produced by sentinel cells and chemokines released from the 
endothelium cause priming of the neutrophil, which is required for later activation [13, 
14]. Next, cytoskeleton rearrangement occurs; the neutrophil flattens and migrates 
through the endothelium (transmigration). Once on the other side of the endothelium, 
inside the tissue, neutrophils follow the signals from the sentinel cells and signals from 
   5 
the “battle field” to the site of infection and are attracted by factors such as IL-8, 
leukotriene B4 (LTB4), platelet activation factor (PAF), complement fraction C5a, and 
bacteria-derived fMLPs, amongst others (Figure 2) [15, 16]. 
 
1.2.3 Bactericidal effector mechanisms 
Neutrophils have an important role in fighting pathogens. They are produced in high 
numbers and if an invader has been detected they are ready to leave the blood and migrate 
to the site of infection. In order to fight pathogens, neutrophils are equipped with a 
number of different killing mechanisms, such as the ability to form extracellular 
neutrophil traps (NETs; which are comparable with spider webs), phagocytosis of the 
invader and subsequent killing, and the release of preformed antimicrobial components 
that are stored in granules (degranulation) (Figure 3). 
 
 
NETs = neutrophil extracellular traps 
Figure 3. Neutrophil killing mechanisms. Adapted and modified from [11]. 
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1.2.3.1 Phagocytosis 
Neutrophils are professional phagocytes that recognize pathogens, engulf them and 
destroy them within the phagosome. This phagocytosis is very efficient and the 
internalization of particles occurs in less than 20 seconds [17]. In contrast, macrophages 
require several minutes for a similar target [18]. The initial step is the recognition of the 
target. For this purpose, neutrophils express different types of Pattern-recognition 
receptors (PRRs), e.g. Toll-like receptors (TLRs), which can directly recognize pathogens 
including bacteria, viruses and fungi by specific pathogen-associated- molecular patterns 
(PAMPs). Examples of such associations between PAMPs and their corresponding TLRs, 
(shown in brackets) include: lipopolysaccharide (LPS) from Gram-negative bacteria 
[TLR4], lipoteichoic acid (LTA) from Gram-positive bacteria [TLR2], bacterial DNA 
[TLR9] or double-stranded RNA from viruses [TLR8] [19]. In addition, indirect 
recognition, which is greatly facilitated by opsonized pathogens coated with antibodies or 
complement components, is performed by Fc and complement receptors [20].  
After recognition and receptor binding, the neutrophil membrane extends around the 
pathogen, resulting in engulfment and uptake and the trapping of pathogen in the 
phagosome. During phagosome maturation, their fusion with endosomes and different 
granules (more details given in 1.2.3.3 Degranulation) induces the release of factors like 
lysozyme, antimicrobial peptides (AMPs), proteases, and MPO (myeloperoxidase) into 
the phagosome, which results in the efficient killing of the engulfed pathogen [21]. In 
addition, oxidative metabolism is up-regulated and provides, through the membrane 
bound NADPH oxidase, the reactive oxygen species (ROS) hydrogen peroxidase (H2O2), 
hydroxyl radical (OH) and hypochlorous acid (HOCl), all of which further facilitate the 
successful killing of pathogens in the phagosome [22-25]. 
 
1.2.3.2 Neutrophil Extracellular Traps (NETs) 
In 2004, a new mechanism of neutrophil killing was described by Brinkmann et al., where 
the authors showed that activated neutrophils form neutrophil extracellular traps (NETs) 
consisting of chromatin DNA, histones, enzymes, AMPs like LL-37 and other granule 
proteins [26]. The released DNA builds a backbone for the granule derived components 
and the formation of NETs occurs 10 minutes after activation [26, 27]. Formation of 
NETs is an additional form of neutrophil mediated cell death, called NETosis. Variations 
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exist between the classical form, called suicidal NETosis and a more recently described 
vital NETosis [28]. Suicidal NETosis is characterized by the rupture of the outer 
membrane, followed by the release of mature NETs and can be induced by, for instance 
PMA or IL-8 [26]. In contrast, neutrophils undergoing vital NETosis preserve an intact 
membrane and maintain their functions [28].  
NETs are able to trap bacteria and prevent them from spreading in the tissue. In addition, 
the presence of high concentrations of serine protease in NETs can kill these trapped 
bacteria either directly or indirectly by cleaving the human cathelicidin antimicrobial 
peptide (hCAP-18) which releases the antimicrobial peptide LL-37 from its C-terminal 
end [26]. It has been documented that this new mechanism of neutrophil killing is relevant 
for the targeting of both Gram-negative, as well as Gram-positive bacteria [26].  
 
1.2.3.3 Degranulation 
Granule types 
Neutrophils develop in the bone marrow and go through different maturation stages: 
myeloblast, promyeloblast, myelocyte, metamyelocyte, band cell and finally a mature 
neutrophil [29]. During these stages, also called granulopoiesis, they produce different 
types of granules in which preformed effector molecules are subsequently stored [30, 31]. 
Neutrophils maintain their dividing potential until the metamyelocyte stage whereas 
granule maturation ends with the mature neutrophil (PMN) (Figure 4) [32, 33].  
 
 
Figure 4. Granule development. Neutrophils develop four types of granules: primary or azurophilic, 
secondary or specific, and tertiary or gelatinase, and secretory vesicles. The development of these granules is 
reverse to the degranulation propensity. Adapted and modified from [12]. 
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When full neutrophil maturation has concluded, which takes approximately 2 weeks [34], 
all 4 granule types have been formed, namely azurophilic granules, also called primary 
granules, specific granules (secondary), gelatinase granules (tertiary) and secretory 
vesicles. The granule/vesicle content is dependent on the development stage of the 
neutrophil and the synthesized proteins are included from promyeloblasts to the band cell 
stage. Factors stored in these granules include antimicrobial components, soluble factors 
of inflammation, components of the respiratory burst oxidase, and adhesion molecules 
(Table 1) (Figure 4) [35, 36]. 
Azurophilic granules have high amounts of myeloperoxidase (MPO) and are also 
characterized by their peroxidase positivity in contrast to the other granules that are 
peroxidase negative [37, 38]. Other important components of azurophilic granules include 
different acidic hydrolases, serine proteases, defensins and bactericidal permeability-
increasing protein (BPI) [39, 40]. These granules play an important role in killing 
pathogens through their fusion with the phagosome and release of azurophilic 
components (Table 1) [41].  
Table 1: Content of neutrophil granules. Modified and adapted from [42]. 
 
R = receptor; * = [43] 
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Specific granules contain proteins such as lactoferrin and NGAL (neutrophil gelatinase-
associated lipocalin) [44] and other antimicrobial components. Upon mobilization they 
fuse with either the phagosome or they release their stored effector molecules by 
degranulation (Table 1) [42].  
Gelatinase granules are rich in MMP9 (matrix metallopeptidase 9), gelatinase, and play 
an important role in the process by which neutrophils leave the blood stream through the 
provision of receptors and matrix-degrading enzymes (Table 1) [42].  
Secretory vesicles contain plasma proteins and other distinct receptors on their 
membrane, which are important for interactions with the endothelium, monocytes, DCs 
and provide neutrophils with a wider repertoire for receiving inflammatory signal    
(Table 1) [42]. 
Release of different granules is not a random process, but rather a closely controlled, 
specific event. Whilst in the blood stream and until the neutrophils have reached the site 
of infection, granules only fuse with the extracellular membrane or the phagosome when 
needed [45]. Therefore secretory vesicles are mobilized first, to facilitate the contact 
between the neutrophils and the endothelium. These are followed by the gelatinase 
granules (during diapedesis), specific granules and finally the azurophilic granules 
(secretory à tertiary à secondary à primary) (Figure 4). 
 
Degranulation Mechanism 
The release of granule components in either the phagosome or into tissue is a tightly 
controlled receptor mediated mechanism which requires Ca2+, ATP (adenosine 
triphosphate) and GTP (guanosine triphosphate) [46]. It involves granule recruitment, 
tethering and docking, priming and finally fusion and release of the granular proteins [46]. 
When neutrophils are at the site of infection and/or have engulfed pathogens, receptor 
recognition induces the remodeling of the actin cytoskeleton, which leads to the 
mobilization of granules in the cytoplasm to the outer membrane for degranulation, or for 
fusion of granules with the phagosome. Once the granules have reached the target 
membrane, they dock and fuse with the membrane, which in turn results in the exocytosis 
of granular components [46].  
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1.2.4 Neutrophil effector molecules 
Neutrophils store pre-synthesized enzymes in granules and generate toxic chemicals for 
killing pathogens in the phagosome. However, killing of extracellular bacteria by 
exocytosis of granule components into the surrounding milieu, can also have harmful 
effects, such as inducing tissue injury (e.g. through proteases) or contributing to the 
disease by increasing vascular leakage (e.g. through HBP) and thereby further 
complicating severe inflammation (Figure 5) [47, 48]. In addition, the lifespan of 
circulating neutrophils is relatively short and “old” neutrophils undergo spontaneous 
apoptosis [49], which requires their subsequent removal by phagocyte efferocytosis to 
prevent lysis and release of granule proteins. Therefore, the recruitment of neutrophils 
needs to be controlled in relation to the level of the threat and removal of apoptotic 
neutrophils is important for maintaining tissue homeostasis [50].  
In my thesis I focus on two neutrophil effector molecules – resistin and the antimicrobial 
peptide LL-37 - which will be described in more detail in the following section. 
 
 
Figure 5. Balancing act of neutrophil killing mechanisms. My thesis is focused on the neutrophil 
degranulation and effects on the host (framed box); negative effects are shown in red and positive effects are 
shown in green. Adapted and modified from [51].  
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1.2.4.1 Resistin 
1.2.4.1.1  Structure and source of resistin 
Resistin, a 108 amino acid, 12.5 kDa peptide hormone, was first discovered in mice in 
2001 and belongs to the resistin-like molecules (RELM) family [52-54]. The name 
“resistin” originates from observations in mice where resistin modulates insulin resistance 
[54].  
In rodents, resistin is strongly detected in adipocytes as well as many other tissues and 
cells [55], whereas, in contrast, human adipocytes are minor producers. Resistin is mainly 
found in human monocytes and neutrophils [43, 56-58], but also in pancreatic islets [59], 
in placental tissue [60], as well as in the plasma [61].  
Mouse and human resistin share only 59% homology at the amino acid level, which might 
explain the distinct functions that have been reported in different species. In the mouse, 
resistin is involved in obesity and type 2 diabetes mellitus [54], whereas in human, it is 
associated with pro-inflammatory conditions such as acute and chronic inflammation [43, 
62-66]. Moreover, its role in insulin resistance and obesity in humans remains to be 
clarified [67-69].  
 
1.2.4.1.2  Resistin in inflammation 
Human resistin contributes to pro-inflammatory conditions by inducing TNF-α and IL-12 
production in macrophages [70] and TNF-α and IL-6 release in PBMCs and adipocytes 
[62, 71]. Activation of the transcription factor NF-κB appears to regulate the 
inflammatory properties of human resistin [70]. The receptor for resistin was only 
recently identified, where studies in humanized mice showed that resistin directly binds to 
CAP1 (adenylyl cyclase-associated protein 1), resulting in inflammatory responses [72]. 
In endothelial cells, resistin stimulates the expression of adhesions molecules (vascular 
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) 
through the p38MAPK (p38 mitogen-activated protein kinase) signaling pathway [73]. 
Similarly, resistin activates same pathway in platelets to increase P-selectin expression 
[74]. Furthermore, resistin is associated with up-regulation of P-selectin and fractalkine 
on monocytes [75]. 
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Up-regulation of adhesion molecules and its role in inducing pro-inflammatory cytokines 
highlight the important role of resistin in inflammation. In patients with rheumatoid 
arthritis, a correlation with increased resistin levels was found [76, 77]. Additionally, our 
group has shown that there is a link between resistin levels and the severity of disease in 
severe sepsis and septic shock [43, 78]. 
 
1.2.4.2 The antimicrobial peptide LL-37  
LL-37 belongs to the cathelicidins family that together with defensins constitutes the 
major classes of antimicrobial peptides (AMP) or host defense peptides (HDPs). 
Cathelicidin peptides are present in many species, suggesting they have an important 
immune role in many organisms [79]. These peptides exhibit antimicrobial activity 
against different types of pathogens, such as viruses, parasites and bacteria.  
 
1.2.4.2.1  Structure of LL-37 
LL-37 is the only member of the cathelicidin-family found in humans and it was 
discovered simultaneously in 1995 by three different groups [80-82]. It was first named 
FALL-39 due to the 39 amino acid sequence at the N-terminus that started with FALL 
[80]. Later it was shown that the active form consists of 37 amino acid residues and 
therefore the peptide was named after the two leucines (LL) at the N-terminal end. LL-37 
is an amphipathic α-helical peptide and is expressed as the precursor hCAP-18, which has 
a molecular weight of 18 kDa. It consists of a signal peptide, made up of the typical 
cathelin domain and an active peptide at the C-terminus (Figure 6). Once the peptide has 
reached its destination – either the cell membrane or the granules – the signal sequence is 
removed by cleavage and the proprotein is stored in an inactive form [83]. 
 
 
Figure 6. The only human cathelicidin, hCAP18 and its C-terminal peptide LL-37. Adapted and 
modified from [83]. 
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1.2.4.2.2  Expression and regulation 
Cathelicidins are a central component of the first line of defense against pathogens and 
are expressed in different cell types and tissues that are exposed to direct contact with the 
environment. The human cathelicidin LL-37 is found in different epithelial cells, for 
instance, the intestine, lung and skin but also in many immune cells including neutrophils, 
monocytes, macrophages, DCs, NK cells, lymphocytes and mast cells [84, 85]. In 
neutrophils LL-37 is stored in specific granules in its proform [86], whereas in 
keratinocytes the expression can be induced, e.g. during inflammatory disorders [87]. 
Only when neutrophil specific granules fuse with azurophilic granules or during NET 
formation with the release of the protease 3, can the inactive form be cleaved, producing 
active LL-37 peptide [88].  
 
1.2.4.2.3  Antimicrobial effect 
LL-37 has broad antimicrobial activity against both Gram-positive and Gram-negative 
bacteria as well as against fungi and viruses. The bactericidal action of LL-37 is exerted 
via the disruption of the bacterial membrane by the toroidal pore mechanism [89]. 
Bacterial membranes, in contrast to mammalian cells, are more negatively charged, due to 
the presence of anionic phospholipids and LPS in Gram-negative bacteria and teichoic 
acids in Gram-positive membranes [90]. This enables an electrostatic interaction between 
these negative components and the cationic properties of LL-37.  
Through the formation of oligomers, LL-37 can reach the outer membrane of bacteria, 
where it binds in parallel to the bacterial surface. This allows the positively charged 
amino acids of LL-37 to interact with the head groups of the negatively charged 
phospholipids. As a result of this, the bacterial membrane bends and a toroidal hole is 
formed [91, 92]. This leads to the disruption of the bacterial membrane, loss of membrane 
potential, leakage of cellular components and subsequent killing of the bacteria [89, 91]. 
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1.3 STREPTOCOCCUS PYOGENES AND STAPHYLOCOCCUS 
AUREUS 
1.3.1 Streptococcus pyogenes 
Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a Gram-
positive bacterium, which lives under facultative anaerobic conditions. It grows in chains 
or pairs and induces beta-haemolysis. The ability of S. pyogenes to induce the production 
of pus gave it its name, which originates from the Greek pyo (pus)-genes (forming) and 
kokkos (berries). S. pyogenes is an exclusively human pathogen and can cause infections 
ranging from those that are mild to more severe and potentially life-threating infections. 
 
1.3.1.1 Non-invasive and invasive infections 
S. pyogenes causes a range of uncomplicated skin and soft tissue infections, e.g., impetigo 
or erysipelas/cellulitis (Table 2). The most common, non-invasive S. pyogenes infections 
occur in the throat, i.e. tonsillitis and pharyngitis, with an estimated 616 million cases per 
year worldwide [93]. Penicillin is the antibiotic of choice for treatment against S. 
pyogenes, as it remains uniformly susceptible to this antibiotic [94]. However, recurrent 
throat infections can occur, which may be caused by the ability of S. pyogenes to hide 
inside pharyngeal epithelial cells after antibiotic treatment, as shown by Osterlund et al. 
[95].  
 
Table 2. Infections caused by S. pyogenes 
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S. pyogenes might also cause invasive infections, including bacteremia, pneumonia, 
necrotizing fasciitis (NF), sepsis and streptococcal toxic shock syndrome (STSS), which 
are associated with marked morbidity and mortality (Table 2) [93, 96]. Listed as number 
9 on the list of global killer pathogens, S. pyogenes induces an estimated 500.000 deaths 
yearly [93]. Characteristics of these severe invasive infections include multiple organ 
failure, hypotension and shock, systemic toxicity, rapid necrosis of tissue and skin, and 
severe local pain [96].  
In addition, S. pyogenes infections can lead to post-streptococcal sequelae such as 
rheumatic fever, rheumatic heart disease, glomerulonephritis, and arthritis, amongst 
others. Children and young adults with untreated pharyngitis can develop acute rheumatic 
fever (ARF), which in some cases can lead to rheumatic heart diseases and subsequent 
heart failure and death [97].  
 
1.3.1.2 Epidemiology 
Streptococcus pyogenes isolates can be identified by three different serological and one 
genotypic classification systems: 
- M serotyping 
- T serotyping  
- Serum opacity factor (SOF) 
- emm-sequencing 
The oldest method is M-typing, introduced in 1928 by Rebecca Lancefield [98]. This 
method is based on the surface-expressed M protein. In addition, serological typing can be 
based on another protein – the T-antigen [99] or alternatively, on the serum opacity factor 
[100]. Today, emm-sequencing is the most commonly used method, which is PCR based 
and allows the distinction of different M types strains as well as variants within an emm-
type [101].  
Some M types can be associated with clinical phenotypes, as they are overrepresented in 
these diseases, e.g. M1 and M3 types are commonly associated with invasive infections, 
such as STSS and NF (including M28), whereas M28 is the only type associated with 
puerperal sepsis, due to its virulence factor R28, which promotes adherence to vaginal 
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mucosa. In addition, M1 and M12 are associated with meningitis and M5 and M18 with 
epidemic ARF, which illustrate a few examples [102]. 
 
1.3.1.3 Virulence factors 
Streptococcus pyogenes is an exclusively human pathogen, and it has adapted to its host 
through the expression of different virulence factors specific for humans (Table 3). 
Generally, surface virulence factors help the bacteria to initiate contact with host cells and 
to hide from the immune system, while secreted virulence factors assist in the 
dissemination into tissues and the generation of nutrients for the growth of the bacteria 
[103]. 
 
Table 3.  S. pyogenes virulence factors. Modified and adapted from [103]. 
 
Spe (A, C, G, M) = streptococcal pyrogenic exotoxins; SSA = streptococcal superantigen; SmeZ = 
streptococcal mitogenic exotoxin 
 
1.3.1.3.1 Surface virulence factors 
A number of important surface virulence factors exist, and amongst others, they include 
the capsule, different adhesion proteins and the M protein. The capsule consists of 
hyaluronic acid, which is similar to host hyaluronan and therefore a poor immunogen 
[104]. All these aforementioned virulence factors inhibit phagocytosis directly, or 
indirectly by interfering with opsonization by the complement system or through 
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antibodies. This antiphagocytic effect is also mediated through the M protein [105, 106], 
M like proteins [107, 108] and C5a peptidase (Table 3) [109].   
One of the best-studied surface virulence factors is the M protein. I will use this molecule 
as an example of the different evasion strategies that are also employed by many other 
streptococcal surface proteins. The initial task of GAS is to attach and adhere to the host 
cells or tissue e.g. in skin infections, the M protein facilitates attachment to keratinocytes 
[110].  
The binding of different components of the host extracellular matrix (ECM), such as 
collagen and fibronectin (Fn) facilitates the adhesion of the bacteria to host cells [111-
113]. Other surface factors that can bind Fn are protein F1, protein F2, FbaA, FbaB, SfbI, 
SfbII and SOF [114]. 
The second important role of adhesins is to avoid recognition and elimination by the 
immune system. Opsonization and thereby phagocytosis can be inhibited by interfering 
with the complement cascade. The M protein binds to the C4b binding protein (C4BP) 
[115], which is a human complement inhibitor, and thus prevents opsonization and 
phagocytosis. Similar functions have been described for attaching Factor H and Factor H 
like proteins [106, 115, 116]. A passive method used by S. pyogenes to escape the 
complement is achieved by binding components from the blood, like albumin and 
fibrinogen which hides the bacterial surface from complement binding [117]. Other 
fibrinogen binding proteins include: Sfb1/PrtF1 and F2, M-like proteins and Mrp [118] 
Surface bound M protein can be cleaved by the streptococcal cysteine protease SpeB. The 
soluble form can build complexes with fibrinogen, which in turn activates neutrophils 
resulting in degranulation and a subsequent increase in the inflammatory response, as well 
as increased capillary permeability and consequently vascular leakage [119]. In addition, 
the M protein can induce a massive T cell response, inflammation [120, 121] and it also 
plays a role in bacterial internalization and invasion [122, 123].  
Most of the adhesion proteins are covalently anchored in the bacterial membrane by the 
typical LPxTz motif, in a similar way to the aforementioned proteins. S. pyogenes also 
expresses five anchorless adhesins that are involved in glycolytic processes, such as 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphoglycerate kinase (PGK), 
α-enolase, phosphoglucerase mutase and triosephosphate isomerase [124]. 
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1.3.1.3.2  Secreted virulence factors 
Characteristics of invasive infections consist of systemic toxicity and tissue destruction 
caused by secreted virulence factors [125]. Hyaluronidase is one of the enzymes which 
facilitates the degradation of hyaluronic acid in connective tissue, thereby facilitating the 
spread of infection [126]. Streptokinase (Ska) has an indirect influence on the spread of 
the infection through tissue by activating the host zymogen form plasminogen to plasmin. 
Active plasmin then dissolves the fibrin barriers therefore helping GAS to spread [103, 
127]. Another important virulence factor is the cysteine protease SpeB (Table 3). This 
secreted factor is not only capable of degrading several host factors e.g. immunoglobulins 
[128], chemokines [129], fibrinogen [130, 131], plasminogen [132] and LL-37 [133, 134], 
but also several of its own factors such as Protein F1 [135], streptokinase [136] and Sda1 
[137]. DNases, expressed by S. pyogenes, help to degrade the DNA backbone of NETs, 
thus impairing the killing mechanism [27, 138].  
S. pyogenes exerts its systemic toxicity via the expression of different types of 
superantigens and two hemolysins. Streptococcal hemolysins, Streptolysin O and S (SLO 
and SLS), can form pores in the membranes of host erythrocytes [139, 140], neutrophils 
[103] and platelets [141]. SLO (oxygen labile) binds to host membranes as monomers 
which are rich in cholesterol [142], following oligomerazation thus causing the 
development of pores [139, 143]. It has been suggested that SLO is associated with 
invasive infections as its expression levels are higher in invasive S. pyogenes isolates 
compared to non-invasive isolates [144]. Neutrophil function was not only impaired 
through lysis, but sub-lytic concentrations of SLO early in infection suppressed the 
oxidative burst and NET formation [145]. SLO-triggered aggregation of neutrophils-
platelets complexes is suggesting a role for SLO in vascular dysfunction in severe 
infections [146]. In addition, SLO can trigger an exaggerated neutrophil response, which 
results into the release of pro-inflammatory mediators [147]. SLS (serum soluble) is, in 
contrast to SLO, oxygen stable, but thermo-labile. Recently, the mechanism behind the 
lysis in erythrocytes has been identified; SLO disrupts the anion exchange protein, band 3, 
thereby initiating the influx of Cl, following lysis (Table 3) [140]. 
Superantigens (SAgs) can contribute to diseases such as STSS and NF by inducing a 
“cytokine storm” and therefore contributing to both shock and organ failure [148-150]. 
They can bind simultaneously as unprocessed, intact molecules to the variable β-chain of 
the TCR and MHC class II molecule on antigen presenting cells [151, 152]. This results 
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in substantial T cell activation, which is associated with an excessive release of pro-
inflammatory cytokines, e.g. IL-1 and 2, TNF-α, TNF-β and INF-γ (Table 3) [151, 153].  
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1.3.2 Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive, catalase- and coagulase-positive bacterium and 
lives under facultative anaerobic conditions. S. aureus typically grows in grape-like 
clusters, and is part of the human flora of the skin and nasal mucosa. About 30% of the 
nasal flora is asymptomatic colonized by S. aureus [154, 155]. The name aureus 
originates from the golden pigmentation of the colonies (latin “aurum” for gold) and 
Staphylococcus from the Greek word for grape “staphylos” and kokkos “berry”. 
 
1.3.2.1 Infections and epidemiology 
With respect to S. aureus infections the increased development of antibiotic resistance, 
especially against penicillin, is of great concern. Methicillin-resistant S. aureus (MRSA) 
is resistant to penicillin and all other β-lactam antibiotics and causes the majority of 
hospital-acquired infections [156-158]. MRSA infections are associated with higher 
mortality and morbidity and are costly for the health system due to longer stays in 
hospital, when compared to methicillin-susceptible S. aureus (MSSA) [159]. The 
infections range from mild skin infections e.g. abscesses, to invasive and life-threatening 
infections such as pneumonia, sepsis, and infective endocarditis, amongst others [160]. 
However, people who are colonized by S. aureus are at greater risk of developing 
infections [161]. Between 2003 and 2005, around 400.000 S. aureus infections occurred 
each year in the USA, whereof 20.000 patients died in the hospital [162, 163]. 
S. aureus is recognized as major cause of hospital-acquired (HA) infections. However, in 
the last decade the separation between community-acquired (CA)- and HA-MRSA has 
become less defined, as CA-MRSA strains have infiltrated the hospital and replaced HA-
MSRA strains [164, 165]. This infiltration and replacement suggest that some CA-MRSA 
strains are more aggressive in terms of virulence and transferability. CA-MRSA has 
remained more sensitive to antibiotic treatment due to the lack of multiple antibiotic 
resistances, apart from the penicillin resistance [159, 165]. 
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1.3.2.2 Virulence factors 
S. aureus expresses a wide range of secreted and surface bound virulence factors to enable 
survival in the host and to escape the immune response. Surface virulence factors like 
protein A (know from many biological assays by virtue of its affinity to the Fc-portion of 
antibodies), fibronectin-binding proteins, and clumping factors, amongst others, can 
promote adhesion to host cells and tissue, invasion and internalization and also help the 
bacterium to escape phagocytosis. Secreted virulence factors such as superantigens, 
cytolysins (e.g. alpha toxin, bi-component leucocidins (BCLs) such as PVL (Panton-
Valentine Leukocidin) etc.), and exoenzymes play a major role in the outcome of 
infection as well [166, 167]. 
For the purpose of my thesis, the bi-component leucocidins (BCLs) are described in more 
detail below. I have focused on these as all BCLs have been shown to have a cytotoxic 
effect against several immune cells including human neutrophils [168]. 
 
1.3.2.2.1 Bi-component pore-forming leucocidins 
In human infections, four different S. aureus bi-component leucocidins have been 
identified; PVL, two forms of γ-hemolysin (HlgAB and HlgCB), LukED, and LukAB 
(also known as LukGH) (Table 4). Each leucocidin consists of two components named 
after their elution profile S (slow) and F (fast) [169]. The S subunit establishes the first 
contact with the host cell by recognizing a specific receptor. After the S subunit binds to 
the target cell receptor it recruits the F subunit [170], which is followed by dimerization 
and results in an oligomer structure. This oligomer consists of 4 S and 4 F subunits that 
form a β-barrel pore in the host membrane (Figure 7) [171, 172]. This characteristic β-
barrel pore formation is also a feature of the cytotoxin α-toxin, however the α-toxin 
oligomerization only requires 7 components [173, 174]. While α-toxin is not toxic to 
neutrophils, all bi-component leucocidins are (Table 4).  
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Figure 7. Mechanism of pore formation of bi-component leucocidins (BCLs). BCLs are composed of an 
S-subunit (S) and an F-subunit (F). After secretion (1), S binds to a specific receptor (grey) on the target cell 
(2a). Following recruitment of the F component (2b) and dimerization; oligomerization (3) and insertion (4) 
occur. Modified and adapted from [168, 175].  
 
A common feature of PVL, γ-hemolysin and LukED is that they all target chemokine and 
complement receptors, which might result from the high sequence similarity of the toxins 
with each other (60-80%) [176]. In contrast, the LukAB sequence matches the other 
toxins by 30-40% and instead, it targets an integrin subunit (Table 4) [176-178].  
PVL is present in only 5% of all strains and those PVL-positive strains are 
epidemiologically associated with severe infections such as necrotizing pneumonia [179, 
180]. However, there are also contradictory studies and opinions regarding the role of 
PVL in infections. Some studies suggest that PVL is not the major factor contributing to 
disease, while others argue that the presence of PVL can even be beneficial for the 
outcome of the infection [176]. However, the fact that PVL only elicits a cytotoxic effect 
in rabbit and human cells makes results acquired from murine and primate animal models 
questionable [181]. LukS-PV targets C5aR and C5L2 [182] and can contribute to acute 
inflammation by inducing the release of IL-8, histamine and LTB4 [168]. At sub-lytic 
concentrations it has been shown that PVL can alter gene expression in neutrophils, which 
leads to enhanced killing of S. aureus (Table 4) [183].  
The two forms of γ-hemolysin (HlgAB and HlgCB) have different S subunits (HlgA or 
HlgC) but share the same F subunit (HlgB) [184] and are found in 99% of all strains 
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[185]. γ-hemolysin also targets red blood cells and it has been shown that the genes hlgA, 
hlgB and hlgC are up-regulated in the blood stream during infection and this contributes 
to S. aureus survival [186]. HlgAB targets the chemokine receptors CXCR1 and 2 and 
CCR2, while HlgCB targets the complement receptors C5aR and C5L2 (Table 4) [187].  
 
Table 4. Characteristics of S. aureus α-toxin and leucocidins. Modified and adapted 
from [168]. 
 
DC = dendritic cell, NK cell = natural killer cell, RBC = red blood cell 
 
70% of S. aureus strains express LukED, which has no species specificity and targets a 
broad range of different cell types [168, 188]. It lyses macrophages, DCs and T cells by 
interacting with the receptor CCR5, while in contrast, in neutrophils, monocytes and NK 
cells the receptors CXCR1 and 2 are used to build a pore (Table 4) [189, 190].  
The strain distribution of LukAB is currently not known, which might be due to its most 
recent identification [177, 191]. It can be either secreted or attached to the bacterial cell 
surface [177]. In contrast to the other leucocidins, LukAB targets an integrin – CD11b – 
which is part of the Mac1 complex on neutrophils, macrophages and monocytes [178]. 
Furthermore, it has been shown that LukAB can promote NET formation (Table 4) [192]. 
S. aureus leucocidins are powerful tools utilized by the bacteria to prevent killing by 
phagocytes and they contribute to the outcome of the infection by induction of 
inflammation and tissue damage [168]. This makes it essential and necessary to gain 
insight in every single leucocidin interaction to find possible targets for new treatments. 
  24 
1.4 IMMUNE EVASION STRATEGIES 
S. pyogenes and S. aureus are human pathogens that share many characteristics. They are 
both part of the human flora - S. pyogenes colonizes the mouth and respiratory tract in 2-
5% of the population, whereas S. aureus commonly inhabits the skin and anterior nares 
(up to 30%). However, they are also capable of causing invasive diseases, such as septic 
shock. Both pathogens have developed many immune evasion mechanisms to avoid or 
prevent an immune response [193].  
For instance, both pathogens express surface virulence factors, so called MSCRAMMs 
(microbial surface components recognizing adhesive matrix molecules) that can recognize 
and bind extracellular matrix molecules. One of these molecules is fibronectin, which is 
bound by the streptococcal M protein [194] among others, and by the staphylococcal 
FnBPA and FnBPB [195]. This binding helps both pathogens to attach to the host (cells or 
tissue) and to hide from the immune system, when bound to the cell surface. 
Another evasion strategy is the avoidance of opsonization by the complement or by 
antibodies. Clumping factor A [196] from S. aureus and M proteins [197] from S. 
pyogenes bind fibrinogen which prevents the binding of the complement opsonization 
factor C3b. Furthermore, proteases such as the cysteine protease SpeB (S. pyogenes) and 
the serine protease V8 (S. aureus) are capable of cleaving C5a and IgG, thus protecting 
the bacterium [198-201]. 
An additional shared feature is the ability to inactivate host effector molecules like the 
antimicrobial peptide LL-37, as seen with SpeB [202] or aureolysin, which is expressed 
by S. aureus [203]. Moreover, the expression of DNases provides an escape mechanism 
from NETs [27, 138, 204]. 
Cytolytic toxins such as BCTs and phenol-soluble modulins (S. aureus), or the 
streptococcal hemolysin SLO, can damage host cells such as neutrophils, which resulting 
in cell lysis. This is a very important mechanism to prevent phagocytic killing [193].  
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AIMS 
This project builds on the hypothesis that neutrophil activation might not only represent 
an important bacterial clearance mechanism, but also a central event in the pathogenesis 
of severe invasive S. pyogenes and S. aureus manifestations. To this end, the project 
focused on dissecting the interactions between neutrophils and these pathogens, and 
aimed to identify bacterial factors involved in neutrophil activation, the resulting 
neutrophil responses and functional consequences of these bacteria-neutrophil interactions 
(Figure 8). 
 
Specific aims include: 
• Determine the neutrophil responses to defined S. pyogenes clinical strains and 
identify streptococcal factors involved in neutrophil activation (paper I).  
 
• Explore the ability that LL-37, the neutrophil derived effector molecule, has on 
influencing streptococcal virulence (paper II). 
 
• Investigate the neutrophil response to defined Staphylococcus aureus leukotoxins 
in relation to their cytotoxic activity (paper III). 
 
 
Figure 8: Schematic presentation of the aims of this PhD project. 
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RESEARCH APPROACH 
The experimental techniques used in this thesis are described in detail in the respective 
papers and manuscript. 
 
Bacterial work: 
All strains that were used in paper I-III are clinical isolates handled with minimum 
passaging. The use of clinical isolates that have been minimally passaged has the 
advantage that they are likely to retain their virulent properties. In contrast, laboratory 
strains have adapted over the years to rich media and a lack of challenges from the host 
making them less virulent. However, it should be recognized that the in vitro culture of 
the clinical isolates in the rich THY medium for S. pyogenes and CCY for S. aureus may 
alter the virulence properties, when compared to the growth in the patients. A challenge 
posed with in vitro experiments is the fact that different culture media and different 
growth phases will alter the virulence profile of the bacteria. In our studies, we mostly use 
stationary phase bacteria (typically 18h cultures) grown in rich media, supporting a high 
exotoxin production (Figure 9 and 11). This was chosen as it somewhat resembles the in 
vivo situation, as studies in patients have shown a high bacterial load and greatly elevated 
expression of exotoxins plus other virulence factors, such as M protein, at the site of 
infection [119, 149, 205]. 
 
Figure 9. Experimental approach to study the effect of LL-37 on bacterial growth/killing and on 
surface alterations. Streptococcal over-night (ON) cultures (18h cultures) were used for all experiments 
with incubation of ± LL-37. The growth was analyzed by CFU counts or OD measurement. Morphological 
surface alterations were studied by confocal and FESE microscopy. 
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To monitor bacterial growth over time we used the Bioscreen C assay, which is a 
computer-based approach that measures optical density (OD) of bacterial cultures  
(Figure 9). Parameters like temperature, shaking and the time intervals between 
measurements can be precisely adjusted. This method for measuring the turbidity of cells 
is ideal for large screening experiments with many parameters and can be used to get a 
general idea about the growth behavior of different bacterial strains and/or conditions (e.g. 
+/- LL-37). However, it cannot be directly translated into bacterial CFUs (colony forming 
units) (Figure 9). As shown in paper II, the increase in turbidity was linked to the 
production/release of extracellular-like structures and not to increased bacterial numbers. 
The experimental approach that we used for investigating the properties of these vesicle-
like structures are shown in Figure 10. 
 
Figure 10. Experimental approach to study the properties of extracellular vesicle-like structures. After 
incubation with LL-37, the bacterial cultures were ultra-centrifuged. The “vesicle-enriched pellet” was used 
to analyze the protein contents with mass-spectrometry. For visualization and comparison of the protein 
content, samples were run on a SDS gel and silver stained. The stimulatory effect of vesicles was examined 
by stimulation of primary neutrophils (PMNs) and neutrophil supernatants analyzed by the amount of 
resistin release (ELISA). 
 
Confocal microscopy is a widely used technique to investigate the interactions between 
LL-37 and bacteria and gives a good overview of the binding pattern. Therefore we used 
this technique to compare our findings with other studies, i.e. reports on interaction of LL-
37 with the ExPortal [206-208]. However, the resolution was not high enough to visualize 
interactions and membrane alterations. To investigate where and how LL-37 interacts 
with the bacterial surface, we utilized the knowledge and expertise of our collaborators in 
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Germany. By employing electron microscopy with much higher magnification and 
resolution, we were able to look at single peptide-bacteria interactions (field emission 
scanning electron microscopy (FESEM)) as well as morphology changes of the 
membrane. Transmission electron microscopy (TEM) and negative staining of the 
bacteria induces the contrast of the sample and reveals morphological changes within the 
cell (Figure 9).  
 
Neutrophil work: 
We used primary human neutrophils isolated from whole blood and collected from 
volunteers for all experiments. Neutrophils are short-lived cells that undergo apoptosis if 
not used shortly after isolation. Therefore the experiments were planned well in advance. 
In addition, the time of the isolation plays a crucial role as the immune system is under 
circadian control [209]; in the beginning of the active phase (after resting) the immune 
system has a much stronger reaction compared to later in the day [209, 210]. Therefore, 
we always tried to isolate and stimulate them around the same time. Another drawback 
with primary cells is the donor variations, which is apparent with the numbers of cells 
isolated and the neutrophil response profiles to different stimuli. In addition, working with 
primary neutrophils requires careful handling, as these cells are easily activated during the 
isolation process. However, to date, there is no suitable human cell line available to study 
the neutrophil degranulation response. An alternative option could have been the use of 
the human leukemia cell line HL-60 [211], which can be differentiated into neutrophil-
like cells [212]. However, these differentiated cells only contain azurophilic granules and 
lack the other types of granules and vesicles [213].  
In order to analyze the neutrophil response by mass spectrometry, we adjusted the 
experimental conditions to minimize any disturbance caused by the mass spectrometer. 
Therefore, we used HBSS (hank`s balanced salt solution) without FCS (fetal bovine 
serum) or plasma, instead of RPMI. 
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Figure 11. Experimental approach to study the effect of bacteria towards neutrophils. Cell-free 
supernatants from over-night cultures of either S. pyogenes and S. aureus and/or S. aureus toxins were used 
to stimulate neutrophils (PMNs). The effect on neutrophil activation/degranulation and cytotoxicity was 
analyzed by measuring resistin and LDH, respectively. The whole neutrophil secretome was evaluated by 
mass-spectrometry and the presence of selected proteins was confirmed via western blot. 
 
After stimulation with different bacterial components (cell-free supernatants, recombinant 
toxins or extracellular-vesicles) the neutrophil response was determined by measuring 
lactate dehydrogenase (LDH) as a measure of cytotoxic effects, or the amount of released 
resistin (ELISA) (Figure 11). We used resistin as a degranulation marker, as this protein 
is stored in azurophilic granules and previous work in our group identified that this factor 
is associated with the severity of sepsis and septic shock [43, 78]. Triton-X was used to 
determine the total amount of resistin and the cytotoxic response. 
To fully characterize the neutrophil secretome profile, proteomic analyses were conducted 
at the core facility at KI for Mass-spectrometry analysis (Figure 11). Label-free 
quantitative mass spectrometry proteomics was used, which revealed information about 
proteins present in neutrophil supernatants (paper I and III). Similarly, mass 
spectrometry was utilized to identify factors present in bacterial supernatants (paper I 
and II) (Figure 10). In addition, Western Blot analysis further confirmed the presence of 
selected proteins found by mass spectrometry (Figure 11). 
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RESULTS AND DISCUSSION 
1.5 STREPTOCOCCUS PYOGENES VERSUS NEUTROPHILS 
(PAPER I AND PAPER II) 
In paper I and paper II we focused on S. pyogenes and neutrophils. In paper I we were 
interested in the neutrophil response to different streptococcal strains and on identification 
of novel bacterial factors involved in neutrophil degranulation, whereas in paper II, we 
studied the impact of LL-37 on streptococcus virulence. 
 
1.5.1 Streptococcal PGK triggers neutrophil degranulation (paper I) 
In this study we investigated the following questions:  
a) Are there differences in neutrophil responses towards different group A 
streptococcal secreted factors? And if yes, 
b) Can we identify the key bacterial factors involved in neutrophil degranulation? 
 
1.5.1.1 Neutrophil activation is linked to the absence of SpeB 
In this study, we demonstrated that the neutrophil response to different streptococcal 
supernatants varies depending on the strain tested. Initially we used M1 and M3 strains, as 
these M types are associated with severe streptococcal infections [214]. The M3 strain 
8003 induced a significantly stronger neutrophil response compared to the M1 strain 
5448. We could demonstrate that apart from the neutrophil degranulation marker resistin, 
the whole neutrophil secretome was affected by 8003, as the stimulated neutrophil 
supernatants contained a broader repertoire of different granule proteins than found in the 
5448-triggered neutrophil secretome (Figure 1, paper I).  
However, this was not linked to the M type, but rather associated with the presence or 
absence of SpeB in bacterial culture supernatants. A parallel study in our group showed 
that 8003 lacks the cysteine protease SpeB [215]. This protease is an important virulence 
factor as it proteolytically degrades numerous host factors but of greater importance in 
this study, it also degrades endogenous virulence factors [216]. The significance of SpeB 
absence in 8003, and thereby an increased neutrophil response, was confirmed by the 
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inclusion of several other streptococcal strains with various M types. The SpeB-negative 
strains induced a significantly stronger neutrophil response in comparison to SpeB-
positive strains (Figure 2, paper I). This led us to the hypothesis that the stronger 
neutrophil response must be linked to a streptococcal factor that is susceptible to SpeB 
degradation. To test this, SpeB was inhibited by the addition of the E64 protease inhibitor 
during bacterial growth, and the following neutrophil stimulation showed that the treated 
SpeB-positive strains induced a much stronger neutrophil response (Figure 3 B, paper I). 
In addition, we included a speB-deletion mutant, which showed a similar phenotype to the 
other SpeB-negative strains, namely a stronger neutrophil response in comparison to the 
wild-type strain (Figure 3 D, paper I). These results confirmed our hypothesis that the 
presence or absence of SpeB determines the effect of the bacteria on neutrophils, and it is 
also likely that other bacterial virulence factors are involved, if not degraded, by SpeB.  
Other studies have shown that there is an association between SpeB-negative strains and 
increased virulence. Most of these SpeB negative strains arose through mutations in the 
CovR/S (control of virulence regulatory sensor kinase) system. This two-component 
system regulates about 15% of the streptococcal genes [217] and mutations are associated 
with hypervirulent phenotypes [218]. Virulence factors such as SLO, hyaluronic acid, 
DNase Sda1, M protein, SIC, SmeZ, NAD-glycohydrolase, C5a peptidase and the 
adhesion collagen-like surface protein are shown to be up-regulated [137, 219]. The 
DNase Sda1 [137] as well as hasA (capsule synthetase) and the emm (M protein) genes 
appear to be critical for the selection of SpeB negative mutants in mice [220]. In addition, 
neutrophils exert pressure on the selection of CovRS mutations in vivo, as seen in 
neutrophil-depleted mice the number of strains with mutations in covRS were decreased 
[221]. Furthermore, the SpeB expression was higher in strains isolated from non-severe 
cases in comparison to isolates from severe cases [222]. 
However, other reports exist that implicate SpeB in disease pathogenesis, such as the 
recent study by Olsen et al., where they looked at a large collection of clinical S. pyogenes 
strains and found the majority of clinical isolates express SpeB [223]. In addition, our 
group has shown that soft tissue biopsies from patients with necrotizing soft tissue 
infections contain a mixture of SpeB-positive and -negative strains which were directly 
isolated from patients diagnosed with necrotizing skin and soft tissue infections [215]. 
SpeB has many important biological functions and it seems likely that the role differs 
during distinct stages of the infections. The presence of SpeB might be beneficial in some 
stages during infections, e.g. after entry through the skin, when nutrition is needed, 
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whereas in the later stages of infections, SpeB-negative strains might have an advantage, 
e.g. by not degrading Sda1, and thereby escaping NETs. At present, the role for SpeB in 
streptococcal infections remains elusive, controversial, and needs further investigation.  
 
1.5.1.2 PGK is a novel neutrophil activator 
To investigate which of the secreted bacterial factors are involved in the aforementioned 
neutrophil activation, we used supernatant from the SpeB-negative strain 8003. Heat-
inactivation of the supernatant resulted in a loss of the stimulatory capacity towards 
neutrophils. This indicated that the stimulatory factor is most likely of protein nature 
(Figure 4A, paper I). To further identify particular factors involved in neutrophil 
degranulation, we fractionated the bacterial supernatant based on protein size. The 
fraction with the highest stimulatory capacity towards neutrophils (F2) and also a high 
protein content (Figure 4 B and C, paper I), was used for mass spectrometry analysis. 
Amongst the identified proteins, there was one protein of particular interest – the 
phosphoglycerate kinase (PGK). 
Only few reports have investigated the role and function of this protein. PGK is a 
glycolytic protein and converts 1,3-bisphosphoglycerate to 3-phosphoglycerate by 
producing ATP. In addition, there are reports which identified PGK as one of the 5 
anchorless adhesion molecules present on streptococcal surfaces [124]. Streptococcal 
surface proteins can be associated with the bacterial cell wall in four different ways; with 
peptidoglycan by a LPxTz motif at their C-terminus, through their N-terminal region, via 
non-covalent interactions, or lastly, by a so far unknown mechanism [224]. There are 
reports that the surface associated Group B Streptococcus and S. pneumoniae PGKs 
interact with plasminogen and actin, providing a role as adhesion proteins [225-227]. In 
addition, the pneumococcal PGK inhibits the classical and alternative complement 
pathway by interacting with the membrane attack complex [228]. These other functions, 
which are likely important for virulence, suggest that PGK belongs to the group of 
moonlighting proteins [229]. So far, no additional functions besides the role in glycolysis 
have been reported in S. pyogenes. Therefore, we wanted to test the hypothesis that PGK 
is a potential factor involved in neutrophil activation.  
First we tried to generate a knock-out mutant despite the fact the survival rate prediction 
for a PGK-mutant was only 40%. The efforts to generate a mutant failed, which suggested 
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that this mutation might be lethal as PGK is involved in essential bacterial processes, 
namely the generation of energy in glycolysis. Nevertheless we were able to construct a 
recombinant PGK, which we purified and used in further experiments to investigate (i) 
SpeB-susceptibility and (ii) the stimulatory capacity of this protein towards neutrophils. 
By utilizing SpeB-positive and –negative supernatants from 5448 and 5448AP strains, we 
showed a time-dependent degradation of PGK by the SpeB-positive supernatants   
(Figure 6 A, paper I). The exposure of primary neutrophils to different concentrations of 
PGK alone, or in combination with 5448 supernatant resulted in a dose dependent 
degranulation response. However, the highest response was noted in the samples where 
PGK was added to 5448 supernatants with the SpeB inhibitor E64 (Figure 6 C, paper I). 
This suggested that there are additional co-stimulatory factors leading to increased 
neutrophil activation.  
In conclusion, in this study (paper I), we identified a novel neutrophil stimulatory factor, 
namely PGK, which was found in SpeB-negative streptococcal supernatants. The fact that 
we only found PGK in SpeB-negative strains indicates the broad effector range of SpeB`s 
degradation potential. The occurrence of SpeB-negative strains and their association with 
severe infections suggests that PGK might contribute to the outcome of severe 
streptococcal diseases (Figure 12). 
 
 
Figure 12. Schematic presentation of the results from paper I.  
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1.5.2 LL-37 triggers bacterial vesicle-like structures (paper II) 
Although it has been shown that LL-37 has a great antimicrobial activity against different 
bacteria, S. pyogenes has developed different counter strategies to evade the antimicrobial 
effect (Table 5) [230]. As LL-37 is attracted by negatively charged surfaces, S. pyogenes 
repels the antimicrobial action by three mechanisms that have been identified so far: a) by 
expressing an enzyme that increases the charge of the surface through D-alanylation 
[231], b) by protecting its surface membrane with a hyaluronic acid capsule [220] and c) 
by integrating a specific carbohydrate – glucoroic-B1,3-N-acetylglucosamine – in its cell 
wall, which blocks the LL-37 interaction [232]. 
SIC (serum inhibitor of complement) and M1 protein, are able to interact with LL-37 
directly. The secreted factor SIC [233, 234] and the M1 protein [235], which is attached 
to the surface, bind directly to LL-37 and thereby prevent the antimicrobial action of LL-
37 on the membrane. 
 
Table 5. S. pyogenes counter strategies to evade LL-37 killing. Modified and adapted 
from [230]. 
Category Specific mechanism References 
Repel: 
  DltABC Lipotechoic acid D-alanylation [231] 
HasABC Hyaluronic acid (capsule) [220] 
GacA-L Glucoronic-B-1,3-N-acetylglucosamine [232] 
Intercept: 
  M1 protein Competitive binding [235, 236] 
SIC Competitive binding [233, 234] 
Destroy: 
  SpeB Direct proteolysis [134] 
GRAB Protease recruitment/redirection [133] 
Ska Activation of proteolysis by plasmin [237] 
 
As mentioned earlier, the secreted cysteine protease SpeB is able to cleave host factors, 
including LL-37 [134]. Even when SpeB is trapped in the binding complex of the surface 
bound G-related α2-macroglobulin-binding protein (GRAB) with the circulating α2-
macroglobulin, a host protease inhibitor, SpeB is still able to cleave and degrade smaller 
substances which are small enough to enter this “ SpeB cage” [133]. Thus, S. pyogenes 
creates an LL-37 inhibitory zone on its surface. A further indirect method of destroying 
LL-37 is facilitated by Ska, which recruits plasminogen and cleaves it to its active form 
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plasmin. Plasmin in return then cleaves LL-37 and protects S. pyogenes against its 
antimicrobial activity [237]. 
 
1.5.2.1 LL-37 effect on bacterial growth 
In this study we investigated the effect of sub-lytic concentrations of LL-37 on the growth 
behavior of S. pyogenes and its impact on streptococcal virulence properties. First, strain 
5448 was exposed to different concentration of LL-37 (1-10 µM) and the growth behavior 
of the culture was monitored by assessing turbidity via Bioscreen C. The analysis showed 
that there is a significant increase in OD/turbidity when the bacteria were incubated with 
1 µM LL-37 (Figure 1a and d, paper II). However, this was not reflected in the CFU 
numbers of the same bacterial cultures (Figure 1e, paper II).  
To investigate if the observed effect was limited to strain 5448, or if it is more general in 
nature, we included other clinical isolates of different M-types in the analysis. Except for 
turbidity, we also analyzed the minimal inhibitory concentrations (MIC) and minimal 
bactericidal concentrations (MBC). The data showed that the response to LL-37 varies 
between the strains. There was even inter-strain variation within the same M-type noted. 
In addition, there was no correlation noted between increased turbidity and MIC and 
MBC. 
 
1.5.2.2 LL-37 induces bacterial surface alteration 
Since the increase in turbidity seen in some of the strains was not linked to bacterial 
growth, we employed confocal microscopy to visualize the interactions between the 
peptide and streptococci. After 30 minutes of exposure, we noticed that LL-37 was bound 
to a limited number of bacterial chains (Figure 3, paper II). This might be explained by 
the fact that LL-37 forms oligomers [238]. It is likely that at low concentrations, these 
LL-37-oligomers reach only a few bacterial chains. In addition, it appeared that LL-37 
targeted the bacterial plane of division (Figure 3, paper II). This was in line with the 
observation by Kristian et al., where LL-37 preferentially targeted E. coli that were in the 
process of dividing [239].  
However, the usage of electron microscopy and immune-gold labeling of the LL-37 
antibody revealed that LL-37 did not bind exclusively to the plane of the division, but it 
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was also found in several other areas of the bacteria (Figure 5 c-f, paper II). Of special 
interest was the observation of vesicle-like structures protruding from the bacteria 
membrane in bacteria exposed to either 1 µM or 10 µM LL-37 (Figure 5 c, d; arrows, 
paper II). This was unexpected, as vesicle formation has been a well-known feature of 
Gram-negative bacteria for more than 50 years, but not much is known about the 
production of vesicles in gram-positive bacteria.  
In Gram-negative bacteria, outer membrane vesicles (OMVs) are actively formed by 
pinching off parts of the outer membrane and they have been shown to have a role in 
bacterial pathogenesis and immune regulation [240]. OMVs contain parts of the outer 
membrane, LPS, periplasmic and membrane-bound proteins, enzymes, toxins, DNA, 
RNA and peptidoglycan. The controlled release of OMVs has an impact on bacterial 
virulence, and in addition it has been shown that vesicle release can be related to stress, 
and it also helps the bacteria to communicate with one another plus modulates the host 
immune responses [240-243]. 
Only recently, in the last couple of years, extracellular membrane-derived vesicles (MVs) 
have been described in Gram-positive bacteria, such as Staphylococcus aureus [244], 
Bacillus anthracis [245], and Streptococcus pneumonia [246]. 
 
1.5.2.3 Vesicles formation and impact on neutrophils 
The use of electron microscopy and negative staining of the bacteria confirmed the initial 
finding that LL-37 induces the release of vesicle-like structure on the cell surface of 
streptococci (Figure 4 a-f, paper II). Bacteria treated with high concentrations of LL-37 
(10 µM) showed larger aggregates on their surface, which were connected with the 
cytoplasm. This was also confirmed by field emission scanning electron microscopy 
(FESEM) analysis (Figure 4 i, paper II). About the same time as we found that sub-lytic 
concentration of LL-37 can induce vesicle release (paper II), another study showed that 
sub-lethal concentrations of penicillin have a similar effect on S. pyogenes [247]. This led 
us to investigate the content of the vesicle structures. We identified several proteins such 
as enolase and GAPDH. These proteins belong to the same group as anchorless adhesion 
molecules like PGK. In addition, within the vesicles we also detected M protein, 
streptokinase A, and streptolysin, amongst others (Table 2, paper II). Exposure of 
primary human neutrophils to the vesicle-like structures revealed the immunostimulatory 
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capacity of the vesicles, as seen through neutrophil activation and degranulation     
(Figure 7 c and d, paper II). This was an important finding as invasive streptococcal 
infections are associated with hyper-inflammatory conditions, such as high numbers of 
infiltrated immune cells, high bacterial load and the presence of LL-37 [248]. 
 
1.5.2.4 The role of CovS in vesicle formation  
Furthermore, we explored the mechanism behind the LL-37 induced vesicle formation. A 
report has shown that 10-residues found in LL-37 (RI-10), which lack antimicrobial 
activity, are required for direct interaction with CovS [249]. Our experiments revealed 
that RI10 is also sufficient for inducing vesicle formation, implicating the involvement of 
CovRS in vesicle formation (Figure 6 a, right image, paper II). However, by utilizing 
the natural covS mutant 5448AP, which has defective signaling, as well as 581ΔcovS, we 
showed that these mutants produced vesicles, although they were released in larger 
aggregates in response to LL-37, similar to those seen in the response of 5448 to 10 µM 
LL-37. This indicated a greater antimicrobial permeation effect, which was in line with 
their lower MIC and MBCs when compared to their respective wild-type strain        
(Table 1, paper II). Resch et al. [250] recently investigated the mechanisms behind 
membrane-derived vesicle formation in S. pyogenes and specifically the impact of CovRS 
on vesicle formation and content. They used different covS mutants; one was a covS-
defective strain NS88.2 (emm type 98.1) and the other had a large deletion in covS 
(ISS3348, M1 Type), as well as 5448AP (also used in paper II). All covS mutants 
showed a significant increase in vesicle production in comparison to their respective wild-
type strain or “repaired” strain, by quantification per CFU; this suggested that CovRS had 
a negative impact on vesicle formation [250]. This is similar to our finding, as we saw 
larger aggregates in the covS mutant consistent with a greater antimicrobial effect induced 
by LL-37, rather than increased vesicle formation. Nevertheless, we cannot exclude the 
involvement of CovS and whether or not the effect of CovS is of direct or an indirect 
nature remains unclear. In addition Resch et al. investigated the involvement of SpeB and 
the capsule, as CovS mutations are associated with the loss of SpeB expression and up-
regulation of the capsule. However, both had no effect on vesicle formation [250]. 
In conclusion, this study shows that sub-lytic concentrations of LL-37 can induce vesicle 
formation in S. pyogenes, which may contribute to pathogenesis as the protein content 
induced an inflammatory response in neutrophils (Figure 13). We showed that the 10 
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residues which interact with CovRS (RI-10) [249] and lack antimicrobial activity, were 
sufficient to induce vesicle formation. However, a deletion mutant which lacked CovS 
signaling, and mutant with a covS mutation, showed the same phenotype, namely the 
release of larger aggregates, similar to the effect seen with higher LL-37 concentrations 
and wild-type bacteria. This suggested that CovRS signaling seems to impact the effect of 
LL-37 on vesicle formation but our data suggests that other mechanisms might be 
involved as well. 
 
 
Figure 13. Schematic presentation of the results from paper II. Thin arrow indicates a weak, thick arrow 
a strong neutrophil response. 
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1.6 STAPHYLOCOCCUS AUREUS VERSUS NEUTROPHILS 
(PAPER III) 
1.6.1 Neutrophil responses triggered by leukotoxins (paper III) 
Similar to S. pyogenes, S. aureus have evolved immune evasion strategies to avoid the 
immune response, including phagocytic killing by neutrophils. Therefore, it expresses a 
variety of cell surface and secreted virulence factors that help the bacteria to colonize 
humans or cause a range of infections from uncomplicated skin ones to the very severe, 
such as necrotizing fasciitis or pneumonia. In addition, the bi-component leukotoxins 
(BCLs) are important virulence factors, as they are able to form pores in neutrophils, 
amongst others, which can induce the uncontrolled release of granule proteins. However, 
besides their cytotoxic effect, activation and degranulation of neutrophils has not been in 
investigated in detail. 
 
1.6.1.1 Neutrophil degranulation is independent of cytotoxicity 
In this study we wanted to investigate the neutrophil response to defined BCLs in S. 
aureus supernatants with a focus on activation and cytotoxicity towards neutrophils. First, 
we looked at the clinical isolate LUG2012 (USA300 strain) and its isogenic mutants PVL 
and α-toxin deficient mutants. We saw a significant decrease in cytotoxicity towards 
neutrophils with the PVL mutant, while resistin release was not affected                 
(Figure 1 A and B, paper III). The α-toxin was used as a negative control as it has been 
shown to target other cell compartments, such as epithelial and red blood cells, rather than 
neutrophils [173, 251]. As expected the α -toxin knock-out had no significant effect on 
neutrophil lysis or degranulation, compared to the wild-type strain (Figure 1 A and B, 
paper III). 
The finding that a strong resistin response was even seen after stimulation with the PVL-
mutant (despite its loss of cytotoxic activity), was interesting and we wanted to explore 
whether this was a general feature for BCLs. For this purpose we utilized an additional 
strain, SF8300 (also a USA300 strain), and its isogenic mutant strains deficient in PVL, 
LukED, and LukGH. The ΔLukGH mutant showed a similar cytotoxicity and resistin 
profile compared with the wild-type strain (Figure 1 C and D, paper III). Both mutants - 
ΔPVL and ΔLukED – induced less cytotoxicity. This loss of cytotoxicity was stronger for 
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ΔPVL in comparison to ΔLukED. However, the reduction in cytotoxicity was not 
reflected in changes in the levels of resistin as these were similar in all strains         
(Figure 1 C and D, paper III). Thus, the data shows clear differences between the 
toxins, with PVL even inducing resistin release at sub-lytic concentrations, whereas 
LukED requires lytic concentrations for resistin release. 
To exclude the role of additional secreted factors involved in the noted effect seen with 
the PVL and LukED mutants, we used recombinant toxins. Both toxins induced a dose-
dependent cytotoxic effect towards neutrophils (Figure 2 A, paper III). In agreement 
with the results from the bacterial mutants, with regards to resistin release, LukED 
induced a dose-dependent release, whereas PVL induced an equally high resistin response 
in all concentrations tested (Figure 2 B, paper III). Consistent with this finding, we 
found a positive correlation between cytotoxicity and resistin for LukED (p<0.0001) but 
not for PVL (p<0.014) (Figure 2 C, paper III).  
The S component of LukED (LukE) and PVL (LukS-PV) share 69% similarity while the 
F component LukD and LukF-PV share 82% similarity [176]. Both toxins target 
chemokine receptors. While PVL binds to neutrophils, monocytes and macrophages by 
targeting the receptors C5a and C5L2, LukED interacts with CCR5 on neutrophils, RBCs, 
monocytes, macrophages, DCs, NK cells and T cells (Table 4, page 23) [168]. Major 
differences between these two BCLs include the strain distribution and species specificity. 
While PVL is only found in approximately 5% of the clinical isolates and exerts its pore-
forming effect in only rabbit and human cells, LukED is found in the majority of strains 
(70%) and is toxic across species [168]. In addition, the cytotoxic dose of PVL in human 
cells ranks between 80-100 ng/ml while LukED is only cytotoxic at higher doses, around 
2-5 µg/ml [252]. Despite their sequence similarity and the fact they target the same kind 
of receptor, their effect on neutrophils seems to differ in relation to degranulation, while 
the cytotoxic effects remain similar with a clear dose response effect, albeit at different 
concentrations.  
 
1.6.1.2 Complex neutrophil responses towards LukED and PVL 
To further characterize the noted difference in neutrophil response and particularly 
degranulation/exocytosis, we analyzed, by mass spectrometry, the neutrophil secretome 
triggered by sub-lytic/lytic concentrations of PVL and LukED. A large number of 
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significantly differentially expressed proteins were identified following the different 
stimulations, as compared to unstimulated cells. When comparing the up-regulated 
proteins with regards to protein networks, the sub-lytic concentration of PVL (40 ng/ml) 
induced the up-regulation of proteins that are mainly involved in immune responses 
(Figure 3 B, paper III). Granule proteins such as neutrophil elastase (ELANE), MPO 
and HDPs (LL-37 and defensins 1 and 3) were expressed to a significantly higher extent 
when compared to those seen with lytic concentrations of PVL and LukED            
(Figure 3 C, paper III).  
In contrast to PVL40, the lytic concentrations of PVL and LukED induced a more 
heterogeneous response profile, with changes seen in proteins involved in immune 
responses, the actin cytoskeleton, protein polymerization and other cellular processes 
(Figure 3 B, paper III). Selected proteins, such as the high mobility group protein B1 
(HMGB1), showed a higher expression in the lytic toxin concentrations than with PVL40, 
which is in line with HMGB1 being an alarmin (DAMP) released by necrotic cells 
(Figure 3 C, paper III) [253]. In addition, the two proteins annexin A11 (ANXA11) and 
S100P were up-regulated under all three toxin conditions when compared to unstimulated 
cells (Figure 3 D, paper III). Both proteins are involved in Ca2+ signaling and S100P 
together with HMGB1 belong to the group of alarmins. They are released in response to 
necrotic and damaged cells and are associated with several inflammatory diseases  
(Figure 3 D, paper III) [253, 254]. 
 
1.6.1.3 Potential involvement of JNK in neutrophil lysis 
Next, we sought to identify signaling pathways involved in aforementioned effects. The 
secretome-network analysis indicated the involvement of different proteins in signal 
transduction, such as the Fc-gamma receptor IIIB (FCGR3B), Myristoylated Alanine-
Rich C-Kinase Substrate (MARCKS), and 14-3-3 protein beta/alpha (YWHAB)    
(Figure 3 D, paper III). Therefore, we used inhibitors targeting different steps in MAP 
kinase signaling (i.e. inhibitors for: Src-family kinases, PI3K, MAPK p38, ERK1/2 and 
JNK). The JNK pathway inhibitor (SP) was almost able to completely abolish the 
cytotoxic effect of LukED, while resistin release was partially reduced with all inhibitors 
used. In contrast, no blocking effect in PVL stimulations was noted (Figure 4 A and B, 
paper III). The inhibitory effect of SP on LukED, but not on PVL cytotoxicity is another 
indication of the noted differences towards neutrophil activation between these two 
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toxins. The potential involvement of the JNK pathway, is in line with the findings by Yeh 
et al., where it was shown that this pathway is essential for neutrophil killing of S. aureus 
[255]. However, this particular study used live bacteria, which makes it difficult to draw 
any conclusions in comparison with our study. 
In conclusion, our finding points towards different mechanisms for the two BCLs LukED 
and PVL upon interaction with neutrophils. While the cytotoxic and degranulation 
response towards LukED is dose-dependent, PVL induced a similar resistin response, 
even at sub-lytic concentration and an immune response related secretome profile  
(Figure 14). Other reports have described that sub-lytic concentrations of PVL have 
different effects on neutrophils, besides pore formation. One study reported, that sub-lytic 
concentration of PVL could alter neutrophil gene expression, which results in enhanced 
bacterial killing [183]. Other studies noticed a priming effect [256], induction of apoptosis 
[257, 258] and the release of pro-inflammatory cytokines [258]. These observations might 
explain why S. aureus infections of PVL-positive isolates are associated with a more 
severe outcome. However, the role of PVL is also discussed in association with a better 
outcome for the patients [259-261] and furthermore, there are other studies in which no 
correlation between PVL and the severity of infection has been found [262-264]. Our 
results suggest yet another effect of sub-lytic PVL concentrations, namely induction of 
neutrophil granule exocytosis. Typically, excessive release of these potent granule 
proteins that have been identified in the neutrophil secretome, are associated with 
inflammatory responses and direct toxic effects on cells and tissue. However, this remains 
to be addressed in further studies. 
 
 
Figure 14. Schematic presentation of the results from paper III. 
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CONCLUDING REMARKS AND FUTURE ASPECTS 
The studies of my PhD projects focused on neutrophil interplay with two Gram-positive 
bacteria, S. pyogenes (paper I and II) and S. aureus (paper III); in particular, in light of a 
potential contribution of neutrophils to disease pathogenesis. For this purpose we 
explored the interaction between neutrophils and characterized clinical isolates or purified 
virulence factors. The project sought to identify bacterial factors involved in neutrophil 
activation, the resulting neutrophil response profile and functional consequences elicited 
by neutrophil derived factors (i.e. LL-37).   
 
S. pyogenes and neutrophils 
Paper I: 
Here we explored the impact of S. pyogenes secreted factors on neutrophil activation 
and degranulation and the studies revealed: 
• A marked variation in neutrophil degranulation was noted between different S. 
pyogenes strains. 
• SpeB-negative strains induced a significantly stronger neutrophil response as 
compared to SpeB-positive strains. 
• PGK was identified as a novel neutrophil immunostimulatory factor. 
• This places S. pyogenes PGK among the multifunctional moonlighting proteins 
that have essential roles in glycolysis but also exerts important virulence 
functions.  
The results showing that PGK and neutrophil activation/degranulation were only seen in 
SpeB negative strains is of interest in light of reports describing hypervirulent SpeB-
negative clones that are associated with severe infections. Our data suggests that the 
presence of SpeB-negative variants could result in a greater streptococcal-triggered 
neutrophil activation and degranulation, thereby causing exacerbated tissue damage, 
inflammatory response and systemic toxicity. The clinical relevance of PGK triggered 
inflammation in patients, and the link with SpeB-negative variants remains to be proven 
in future studies. It would also be of interest to investigate if other moonlighting proteins, 
such as GAPDH, would have similar stimulatory effects on neutrophils or other immune 
cells. 
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Paper II: 
In this study, we investigated how the antimicrobial peptide LL-37 influenced S. 
pyogenes with respect to growth, surface architecture and virulence. The study 
demonstrated that: 
• Sub-inhibitory concentrations of LL-37 induce the release of extracellular vesicle-
like structures on the bacterial surface. 
• These vesicle-like structures contained several virulence factors with stimulatory 
activity towards neutrophils. 
• CovRS interaction with LL-37 has an impact on vesicle formation, however it 
seems that other factors might also be involved. 
Vesicle formation is a part of a secretion-delivery system in Gram-negative bacteria and 
has a great impact on bacterial pathogenesis. However, not much is known about vesicles 
in Gram-positive bacteria, and this phenomenon was only recently discovered in a few 
species. Our study was the first report of S. pyogenes forming extracellular vesicle-like 
structures in response to LL-37. We could not exclude CovRS involvement in vesicle 
formation and weather this is an indirect or direct effect of CovRS needs to be explored 
further.  
 
S. aureus and neutrophils 
Paper III: 
We also investigated the effect of the pore-forming S. aureus toxins, PVL and LukED, on 
granule exocytosis in relation to toxin-mediated cytotoxicity, and we showed that:  
• LukED has a dose-dependent effect towards neutrophils, both in regards to 
cytotoxicity and activation. 
• In contrast, PVL induced a dose-dependent cytotoxicity, but even sub-lytic 
concentrations triggered neutrophil degranulation. 
• JNK-pathway inhibitors affected neutrophil degranulation, suggesting a possible 
role in neutrophil response towards BCTs. 
Our results demonstrated that PVL and LukED have different effects on neutrophils and 
that neutrophil degranulation is an independent event and does not require lysis. A 
possible reason for the noted differences between toxins might be that they are targeting 
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different receptors and thereby different signaling pathways. Additional studies are 
necessary to follow up on the potential involvement of the JNK pathway, Ca2+ - and 
FcgR-dependent signaling. Other remaining questions include how the more potent 
neutrophil activation of PVL influences disease pathogenesis, and do other pore-forming 
toxins exert similar effects.  
This project builds on the hypothesis that neutrophil activation might not only represent 
an important bacterial clearance mechanism, but also a central event in the pathogenesis 
of severe invasive S. pyogenes and S. aureus manifestations. To this end, the project 
focused on dissecting the interactions between neutrophils and these pathogens, and 
aimed to identify bacterial factors involved in neutrophil activation, the resulting 
neutrophil responses and functional consequences of these bacteria-neutrophil 
interactions. 
 
 
Figure 15. Schematic summary of results of paper I-III. 
 
In summary, we identified the streptococcal factor PGK, as well as the pore-forming 
toxins from S. aureus as potent triggers of neutrophil activation and degranulation 
(Figure 15). In addition, we show that the antimicrobial peptide LL-37 induces the 
release of pro-inflammatory extracellular vesicle-like structures from the surface of S. 
pyogenes. The studies comprised in this thesis contribute to a deeper understanding of the 
host-pathogen interplay during severe S. pyogenes and S. aureus infections, in particular 
with regards to neutrophil activation and a likely contribution to pathogenesis. 
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